BHBenoit Ho-Tin-Noé

Benoit Ho-Tin-Noé

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benoit Ho-Tin-Noé has a total of 279 co-authors. Here are the top co-authors by number of shared publications:

  • Mialitiana Solo Nomenjanahary

    Optimisation Therapeutique en Neuropsychopharmacologie

    11 shared publications
  • Véronique Ollivier

    Université Paris Cité, INSERM, Optimisation thérapeutique en neuropharmacologie OTEN U1144, Paris, France

    10 shared publications
  • Mikael Mazighi

    Université Paris Cité, INSERM, Optimisation thérapeutique en neuropharmacologie OTEN U1144, Paris, France

    9 shared publications
  • Sébastien Dupont

    Université Paris Cité, INSERM, Optimisation thérapeutique en neuropharmacologie OTEN U1144, Paris, France

    9 shared publications
  • Jean-Philippe Desilles

    Université Paris Cité, INSERM, Optimisation thérapeutique en neuropharmacologie OTEN U1144, Paris, France

    8 shared publications
  • Jean-Philippe Desilles

    Université Paris-Cité, U1144 INSERM, Therapeutic optimization in Neuropsychopharmacology, France (B.H.-T.-N., M.M., J.-P.D.).

    8 shared publications

Latest Publications

  • Open Access

    Predictors of Hemorrhagic Transformation After IV Continuous Cangrelor Infusion Initiated During Mechanical Thrombectomy

    by Andrea Gambino, David Weisenburger-Lile, Aurélien Freiherr von Seckendorff, Manar Abomulay, Marie Ernst, Benjamin Maïer, Pierre Seners, Michel Piotin, Raphaël Blanc, Simon Escalard, et al.

    BACKGROUND: Cangrelor, a fast-acting intravenous P2Y12 receptor inhibitor, is increasingly used during mechanical thrombectomy for acute ischemic stroke to treat or prevent thrombotic complications. While effective, its use may increase the risk of hemorrhagic transformation (HT). We investigated clinical, imaging, and procedural predictors of HT in this specific patient population. METHODS: We performed a retrospective post hoc single-center study including 101 patients with acute ischemic stroke treated with intravenous cangrelor initiated directly after mechanical thrombectomy and continued for 12 hours between January 2021 and June 2024. Univariate and multivariable logistic regression models were used to assess associations between HT and clinical, radiological, and procedural factors. RESULTS: Among the 101 patients included, 25 (24.7%) developed HT, and 9 (8.9%) experienced symptomatic intracerebral hemorrhage. In multivariable analysis, baseline blood glucose (adjusted odds ratio, 6.51 [95% CI, 1.35–31.4]; P =0.02), leukocytosis (adjusted odds ratio, 1.18 [95% CI, 1.00–1.38]; P =0.047), and subarachnoid hemorrhage on postmechanical thrombectomy cone-beam computed tomography (adjusted odds ratio, 16.60 [95% CI, 2.97–92.8]; P =0.0014) were independent predictors of HT. Contrast enhancement was associated with HT in univariate analysis but did not remain significant after adjustment. CONCLUSIONS: Baseline blood glucose, leukocytosis, and isolated subarachnoid hemorrhage on postmechanical thrombectomy cone-beam computed tomography emerged as independent predictors of HT. Identifying high-risk patients using readily available clinical and imaging markers may support individualized antiplatelet strategies and help reduce hemorrhagic complications during cangrelor treatment. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03776877.

  • Engineering a Translational Human Thrombus Platform to Evaluate Clinical Therapies in Ischemic Stroke

    by Charly Helaine, Audrey Picot, Mialitiana Solo Nomenjanahary, Mélina Ianszen, Didier Goux, Christophe Gaudin, Jerome Parcq, Richard Macrez, Benoit Ho-Tin-Noé, Denis Vivien, et al.

    BACKGROUND: Recanalization failure after ischemic stroke remains a major clinical challenge, partly because cerebral thrombi display marked spatial heterogeneity that is poorly reproduced by experimental models. Here, we engineered a translational human blood–based thrombus platform that recapitulates key histological features of patient-derived stroke clots. METHODS: Under controlled conditions, the platform generated reproducible thrombi with pronounced interthrombus and intrathrombus heterogeneity, including alternating red blood cell–rich and platelet-rich territories. Multiscale structural and biochemical analyses confirmed the successful replication of the clinical biphasic organization associated with resistance to rtPA (recombinant tissue-type plasminogen activator): a compact outer fibrin shell containing focal accumulations of plasminogen activator inhibitor-1, and a dense inner core further stabilized by neutrophil extracellular traps. RESULTS: Functional thrombolysis assays demonstrated that this architecture directly dictates lytic susceptibility. Specifically, artificially breaching the outer fibrin shell (halved thrombi) significantly accelerated early rtPA-mediated lysis, proving its role as an effective physical barrier. Furthermore, lytic response was inherently linked to clot composition: platelet-rich thrombi with dense plasminogen activator inhibitor-1 and neutrophil extracellular trap networks exhibited profound resistance to standard rtPA compared with red blood cell–rich clots. Supporting the platform’s translational relevance, this structural resistance was successfully overcome by clinically relevant strategies, including tenecteplase and adjunctive DNAse, consistent with observations from human stroke cohorts. CONCLUSIONS: By accurately reproducing the spatial organization and differential thrombolytic responses of human cerebral thrombi, this translational framework provides a robust preclinical tool to dissect lytic resistance and evaluate next-generation precision reperfusion therapies. Furthermore, developing robust ex vivo human platforms is increasingly critical to align with the replacement, reduction, refinement ethical guidelines for animal research.

  • Open Access

    Neutrophil Extracellular Traps Block Fibrinolysis in Ischemic Stroke

    by Mialitiana Solo Nomenjanahary Msc, Jean-Philippe Desilles, Fatima Zemali Msc, Astride Perrot Msc, Lucas Di Meglio, Sara Zalghout, Jéromine Fasille, Jérémy Neel, Stéphane Loyau Bsc, Julien Labreuche Bst, et al.

    Objectives: Intravenous thrombolysis (IVT) failure in acute ischemic stroke (AIS) is frequent, but its causes remain elusive. We investigated whether biologically relevant intrathrombus concentrations of tissue plasminogen activator (tPA) were achieved in failed IVT and whether neutrophil extracellular traps (NETs) contributed to this therapeutic failure. Methods: In this monocenter cohort study, 205 thrombi from AIS patients were analyzed. A total of 83 of these thrombi were compared for tPA content and 53 for their susceptibility to ex vivo thrombolysis according to IVT status. An additional subset of 69 AIS thrombi was used to decipher if and how NETs interfere with intrathrombus fibrinolysis. Results: Thrombi from IVT patients contained twice as much tPA than those from no‐IVT patients ( p < 0.0001). Plasminogen and tPA in AIS thrombi were associated with fibrin, leukocytes, and NETs. Although ex vivo addition of plasminogen did not cause lysis of either no‐IVT or IVT thrombi, combining plasminogen with deoxyribonuclease 1 (DNase 1) helped translate the increased tPA content of IVT thrombi into increased thrombolysis. We further show that DNase 1 enables tPA‐ and plasmin‐mediated thrombolysis by eliminating fibrinolysis inhibitors from AIS thrombi. Interpretation: These results indicate that intrathrombus tPA concentrations reached in failed IVT bear a therapeutic potential that is impaired by NETs, which favor intrathrombus retention of fibrinolysis inhibitors and may limit the availability of tPA and plasminogen for fibrinolysis. Our results stress the interest of DNase 1 to enhance the efficacy of current IVT tPA regimens. ANN NEUROL 2026;100:964–978

  • Open Access

    Venular-centered thrombo-inflammation drives microvascular failure after arterial recanalization in acute mesenteric ischemia

    by Déborah François, Lambert Kernanet, Melinda Bajul, Abigail Brami, Véronique Arocas, Marie-Christine Bouton, Dominique Cazals-Hatem, Kevin Guedj, Benoit Ho-Tin-Noé, Olivier Corcos, et al.

    Background: Acute mesenteric ischemia (AMI) remains associated with high mortality despite prompt revascularization, suggesting that downstream ischemia–reperfusion injury contributes to poor outcomes. However, the microvascular mechanisms underlying this process are not entirely defined. Methods: We analyzed admission blood samples from patients with arterial AMI and non-ischemic controls enrolled in the SURVIBIO diagnostic study (NCT03518099). We also investigated thrombo-inflammatory responses in a murine superior mesenteric artery occlusion (SMAO) model. In mice, intravital microscopy was used to directly visualize mesenteric microcirculatory flow and thrombo-inflammatory events during ischemia–reperfusion. Results: Patients with AMI display a marked systemic thrombo-inflammatory profile, characterized by elevated inflammatory markers, neutrophil activation, platelet activation, and alterations in coagulation-related proteins, which are closely mirrored in the SMAO model. Intravital microscopy reveals a dissociation between arterial and microvascular reperfusion: while arteriolar flow partially recovers after recanalization, venular perfusion remains severely impaired and is associated with early blood cell stasis and stable venular thrombus formation. Thrombi develop through a sequential process initiated during ischemia and amplified during reperfusion. Conclusion: Together, these findings suggest that venular-centered thrombo-inflammation is closely associated with microvascular dysfunction and intestinal injury in arterial AMI. This work provides a framework for targeting thrombo-inflammatory pathways beyond arterial reperfusion that may extend to other clinical forms of AMI, including non-occlusive mesenteric ischemia (NOMI).


  • Open Access

    Platelets mediate fibrin-induced thromboinflammation and NETosis through a GPVI-polyphosphates-FXIIa procoagulant axis

    by Astride Perrot, Véronique Ollivier, Sandrine Delbosc, Fatima Zemali, Jasmina Rogozarski, Sébastien Dupont, Mikael Mazighi, Eric Camerer, Nathalie Kubis, Martine Jandrot-Perrus, et al.

  • Open Access

    Dual-action nanoconjugate for overcoming r-tPA -resistant clots

    by Audrey Picot, Mandy Leboucher, Charly Helaine, Ankita Talukdar, Igor Khalin, Sara Martinez de Lizarrondo, Maxime Gauberti, Mialitiana Solo Nomenjanahary, Didier Goux, Benoit Ho-Tin-Noé, et al.

    Clot resistance to pharmacological thrombolysis remains a critical challenge in ischemic stroke (IS) management. Thrombus heterogeneity, particularly the presence of thrombolysis-resistant domains composed of dense fibrin and non-fibrin components, including neutrophil extracellular traps (NETs), significantly limits the efficacy of recombinant tissue-type plasminogen activator (r-tPA) and its variant, Tenecteplase (TNK). Consequently, novel therapeutic strategies are urgently required. Emerging evidence suggests that co-administration of deoxyribonuclease I (DNase I) with r-tPA can degrade DNA fibers and enhance clot lysis. In this study, we optimized a previously developed theranostic agent-iron oxide microparticles coated with polydopamine-by dual-grafting both r-tPA and DNase to target resistant thrombi. Using functional ultrasound imaging (fUS) during the acute phase of IS, we demonstrated accelerated reperfusion with this dual-functionalized platform in a r-tPA resistant IS model. Furthermore, MRI analysis confirmed a significant reduction in lesion volume at 24 hours, correlating with improved functional recovery five days post-ischemia.

  • Open Access

    Thromboinflammation dans l’accident vasculaire cérébral ischémique

    by Laurine Bedoucha, Sandrine Delbosc, Jérémy Neel, Jean-Philippe Desilles, Mikaël Mazighi, Benoît Ho-Tin-Noé

    L’accident vasculaire cérébral ischémique résulte de l’occlusion d’une artère intracrânienne, et son traitement nécessite une recanalisation artérielle rapide afin de rétablir la perfusion cérébrale. Les traitements actuels de recanalisation artérielle, la thrombolyse intraveineuse et la thrombectomie mécanique, ont amélioré le pronostic, mais leur faisabilité est restreinte et leur capacité à rétablir une bonne reperfusion cérébrale reste limitée. Des expériences dans des modèles animaux d’accident vasculaire cérébral ischémique, ainsi que des données cliniques, suggèrent que la thromboinflammation serait un facteur clé de résistance à ces traitements, non seulement en limitant l’efficacité de la thrombolyse intraveineuse, mais également en découplant recanalisation artérielle et reperfusion cérébrale. Dans cette revue, nous présentons comment la thromboinflammation contribue à la résistance aux traitements visant à rétablir la reperfusion artérielle et nous discutons des opportunités offertes par les thérapies ciblant ses mécanismes pour optimiser la prise en charge des patients.

  • Open Access

    Neutrophil Activation 24 Hours After an Endovascular Therapy–Treated Acute Ischemic Stroke Is Associated With 3‐Month Clinical Outcome

    by François Delvoye, Benjamin Maier, Mialitiana Solonomenjanahary, Julien Labreuche, Lucas Di Meglio, Véronique Ollivier, Pierre Seners, Michel Piotin, Raphaël Blanc, Simon Escalard, et al.


  • Fibrinogen Depletion Coagulopathy and Hemorrhagic Transformation in Acute Ischemic Stroke Treated With Bridging Therapy

    by Naëiri Pauillac, Dorothée Faille, Mialitiana Solo Nomenjanahary, Mélanie Souvanheuane, Nahida Brikci-Nigassa, Alain Ameri, Tristan Benoit, Francois Delvoye, Benjamin Maier, Benoit Ho-Tin-Noé, et al.

    BACKGROUND: Hemorrhagic transformation (HT) frequently occurs in acute ischemic stroke patients with a large vessel occlusion undergoing endovascular therapy (EVT), significantly impacting functional outcomes. We aimed to determine whether an early fibrinogen depletion coagulopathy (FDC) was associated with HT following bridging therapy (ie, intravenous thrombolysis [IVT] followed by EVT), and to identify its associated factors. METHODS: We retrospectively analyzed prospectively collected data from 296 patients with acute ischemic stroke with a large vessel occlusion who underwent EVT alone or bridging therapy, with fibrinogen levels measured both before baseline imaging and at the start of the EVT procedure. FDC was defined as a fibrinogen level 1.0 g/L from baseline. The primary outcome was the occurrence of any HT at 24 to 36 hours. Secondary outcomes included symptomatic HT, parenchymal hematomas, and 3-month mortality. The relationships between FDC and outcomes were studied using multivariable logistic regression analyses, adjusting for relevant confounders. We also studied baseline characteristics associated with FDC occurrence. RESULTS: Of the 296 patients enrolled, 102 (34.5%) experienced HT, and 54 (18.2%) developed FDC. FDC was strongly associated with IVT use (53/161 [32.9%] versus 1/135 [0.7%] in IVT-treated and non-IVT-treated patients, respectively; P P <0.01). CONCLUSIONS: Following bridging therapy, FDC is a frequent event associated with increased risks of any HT, symptomatic HT, parenchymal hematomas, and 3-month mortality. FDC did not occur following IVT with tenecteplase in our cohort, suggesting that the fibrin specificity of thrombolytic agents may play a pivotal role in its development.


  • Open Access

    Neutrophil extracellular traps block endogenous and intravenous thrombolysis-induced fibrinolysis in large vessel occlusion acute ischemic stroke

    by Jean-Philippe Desilles, compoCLOT study group, Mialitiana Solo Nomenjanahary, Astride Perrot, Lucas Di Meglio, Fatima Zemali, Sara Zalghout, Stéphane Sl Loyau, Julien Labreuche, Marie-Charlotte Bourrienne, et al.

    Background: Intravenous thrombolysis (IVT) failure in acute ischemic stroke (AIS) due to large vessel occlusion (LVO) is frequent but its causes remain elusive. Several non-exclusive mechanisms have been proposed to explain IVT failure, including failed delivery of tPA and inhibition of its activity. We investigated whether biologically relevant intrathrombus concentrations of t-PA were achieved in failed IVT in patients with LVO AIS, and whether neutrophil extracellular traps (NETs) contributed to IVT failure. Methods: In this cohort study, a total of 205 thrombi from AIS patients with LVO were analyzed. 83 of these thrombi were compared for tPA content and 53 for their susceptibility to ex vivo thrombolysis according to IVT status. An additional subset of 69 AIS thrombi was used to decipher if and how NETs interfere with intrathrombus fibrinolysis. Results: AIS thrombi from IVT patients contained more tPA than those from no-IVT patients (0.209 vs 0.093 µg/mg of thrombus, pex vivo addition of plasminogen did not cause lysis of either no-IVT or IVT thrombi, combining plasminogen with DNase 1 helped translate the increased tPA content of IVT thrombi into increased thrombolysis. We further show that DNase 1 enables tPA- and plasmin-mediated thrombolysis by eliminating fibrinolysis inhibitors from AIS thrombi. Conclusions: These results indicate that intrathrombus tPA concentrations reached in failed IVT bear a therapeutic potential that is however impaired by NETs, which favor intrathrombus retention of fibrinolysis inhibitors and compete with fibrin for tPA and plasminogen binding. Our results stress the interest of DNase 1 to enhance the efficacy of current IVT tPA regimens. Clinical Perspective: What is new?: Intravenous thrombolysis increases thrombus tPA content even when it fails to cause arterial recanalization in acute ischemic stroke The fibrinolytic activity of intravenously-administered tPA is blocked by neutrophil extracellular traps in acute ischemic stroke thrombi Neutrophil extracellular traps participate in thrombolysis resistance by retaining fibrinolysis inhibitors and titrating tPA and plasminogen away from fibrin in acute ischemic stroke thrombi DNase 1 can convert increased tPA content into increased fibrinolysis by eliminating NETs-associated fibrinolysis inhibitors in acute ischemic stroke thrombi 2) What are the clinical implications?: Despite therapeutic failure, biologically significant intrathrombus tPA concentrations are achieved following intravenous thrombolysis at current tPA regimens Sequential administration of DNase 1 prior to intravenous thrombolysis could clear the way for tPA and potentiate its fibrinolytic activity for improved arterial recanalization efficacy